BiologyWorks k(now) handheld molecular testing device. Credit: Business Wire.

Digital healthcare platform firm BiologyWorks has announced that its k(now) handheld molecular testing device showed 99.1% accuracy with RT-PCR lab test results in a substantive Covid-19 clinical trial.

Conducted by Locus Medicus in Athens, Greece, the independent clinical study tested 330 asymptomatic and symptomatic Covid-19 patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The clinical laboratory staff collected two bilateral anterior nasal swabs from each patient for the trial.

One swab was tested in the handheld, reusable molecular test while the standard of care CE-Mark RT-PCR lab test was used for the other.

Findings showed that the molecular testing device was 99.1% accurate with the laboratory RT-PCR test results.

BiologyWorks k(now) molecular Covid-19 test is connected with the k(now) PRO digital platform, which provides a complete solution to point-of-care (POC) providers for end-to-end testing management.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device provides results to patients and POC providers simultaneously in 45 minutes.

The company stated that the Los Angeles County Department of Health Services, the University of California Los Angeles (UCLA) and Streeklab in Haarlem, Netherlands, have also conducted independent studies on the BiologyWorks k(now).

Additionally, the molecular testing device’s efficacy was verified with more than 12,000 tests in the company’s Southern California laboratory.

All these studies confirmed that the device provides laboratory RT-PCR quality results.

BiologyWorks CEO Hunt Ramsbottom said: “Our company’s priority is to make lab-quality testing accessible, accurate and affordable for everyone.

“These clinical trials confirm that our handheld, reusable test is among the most accurate for Covid-19.

“We give individuals and providers a highly reliable testing platform, with significantly lower cost per result and shortened time to results.”